Literature DB >> 7492121

Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.

G Andrei1, R Snoeck, E De Clercq.   

Abstract

Resistant herpes simplex virus type 1 strains were obtained under the selective pressure of acyclovir, ganciclovir, bromovinyldeoxyuridine, foscarnet, 2-phosphonylmethoxyehtyl (PME) derivatives of adenine and 2,6-diaminopurine, 3-hydroxy-2-phosphonylmethoxypropyl derivatives of adenine and cytosine, and 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine (S2242). The drug susceptibility profiles of resistant strains point to differences in the modes of action of PME and 3-hydroxy-2-phosphonylmethoxypropyl derivatives and common mechanisms of action of foscarnet, S2242, and PME derivatives against herpes simplex virus type 1 replication.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7492121      PMCID： PMC162798          DOI： 10.1128/AAC.39.7.1632

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance.

Authors:  C B Hwang; K L Ruffner; D M Coen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

2.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis.

Authors:  I Votruba; R Bernaerts; T Sakuma; E De Clercq; A Merta; I Rosenberg; A Holý
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

4.  Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

Authors:  A Gateley; R M Gander; P C Johnson; S Kit; H Otsuka; S Kohl
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

5.  Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.

Authors:  P Collins; B A Larder; N M Oliver; S Kemp; I W Smith; G Darby
Journal:  J Gen Virol       Date:  1989-02       Impact factor: 3.891

6.  Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

Authors:  K S Erlich; J Mills; P Chatis; G J Mertz; D F Busch; S E Follansbee; R M Grant; C S Crumpacker
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

Review 7.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

8.  Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

Authors:  S L Sacks; R J Wanklin; D E Reece; K A Hicks; K L Tyler; D M Coen
Journal:  Ann Intern Med       Date:  1989-12-01       Impact factor: 25.391

9.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

10.  5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives.

Authors:  J Balzarini; E De Clercq
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157
View more
  5 in total

1.  Evaluating phenotype and genotype of drug-resistant strains in herpesviruses.

Authors:  G Andrei; P Fiten; E De Clercq; R Snoeck; G Opdenakker
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

2.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

4.  Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.

Authors:  Masayuki Saijo; Tatsuo Suzutani; Shigeru Morikawa; Ichiro Kurane
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  Intravenous Foscarnet With Topical Cidofovir for Chronic Refractory Genital Herpes in a Patient With AIDS.

Authors:  Agnes Usoro; Alfreda Batts; Juan C Sarria
Journal:  J Investig Med High Impact Case Rep       Date:  2015-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.